Thyroid Eye Disease

Teprotumumab, a human monoclonal anti-IGF-1R blocking antibody, reduced proptosis in a series of patients with non-inflammatory thyroid eye disease (TED), according to a study.

Four patients with non-inflammatory TED were treated with a complete course (8 infusions) of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for subsequent infusions every 3 weeks).

After treatment, there was a mean (SD) reduction…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

Journal Scan

  1. Dec 14, 2020

Use of automated imaging metrics in TED may provide rapid clinical information

The use of automated imaging metrics in thyroid eye disease has the potential to provide rapid clinical information that could identify visual impairments in earlier stages, potentially leading to better treatment options, according to a study.

In this study, 204 CT images of orbits in…